Vertex Pharmaceuticals Q3 FY26: where the revenue came from and where it went
The whole income statement of Vertex Pharmaceuticals for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
- Reported
- Nov 3, 2026
Revenue$3.44B
+12% year over year
Gross profit$2.92B
85% margin
Operating profit$0.71B
21% margin
Net profit$0.65B
19% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 3.44 | 100% | +12% |
| Trikaftakaftrio | 2.44 | 71% | |
| Alyftrek | 0.71 | 20% | +186% |
| Manufactured product other | 0.13 | 4% | |
| Casgevy | 0.10 | 3% | |
| Journavx | 0.06 | 2% | |
| Palsonify | 0.01 | 0% | |
| Cost of revenue | −0.53 | 15% | |
| Gross profit | 2.92 | 85% margin | −2pp |
| SG&A | −0.84 | 25% | +10pp |
| Other | −1.36 | 39% | |
| Operating profit | 0.71 | 21% margin | −18pp |
| Other income, net | 0.07 | ||
| Tax | −0.13 | ||
| Net profit | 0.65 | 19% margin | −16pp |
17 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest